Funding for this research was provided by:
Ontario Institute for Regenerative Medicine
Canadian Institutes of Health Research (MOP57726)
CREST Ontario Research Excellence Fund (GL2-01-042)
Received: 13 October 2020
Accepted: 25 February 2021
First Online: 16 March 2021
: All animal procedures were approved in advance by the Animal Care Committee of the University of Ottawa (Ottawa, Ontario, Canada, protocol number OGH/RI-42).
: Not applicable.
: The funding institution had no role in the conception, design or conduct of the study, data collection or analysis, interpretation or presentation of the data, or preparation, review, or approval of the manuscript. We would also like to declare the following conflicts of interest: DJS holds a patent for MSC therapy for the treatment of acute lung injury and SHJM and YD have received personal fees from Northern Therapeutics Inc. that are outside of this submitted work. The remaining authors have disclosed that they do not have any conflicts of interest.